annual EBITDA:
-$47.79M-$19.21M(-67.20%)Summary
- As of today (July 1, 2025), TRVI annual EBITDA is -$47.79 million, with the most recent change of -$19.21 million (-67.20%) on December 31, 2024.
- During the last 3 years, TRVI annual EBITDA has fallen by -$15.08 million (-46.11%).
- TRVI annual EBITDA is now -400.94% below its all-time high of -$9.54 million, reached on December 31, 2017.
Performance
TRVI EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$10.31M+$1.05M(+9.21%)Summary
- As of today (July 1, 2025), TRVI quarterly EBITDA is -$10.31 million, with the most recent change of +$1.05 million (+9.21%) on March 31, 2025.
- Over the past year, TRVI quarterly EBITDA has increased by +$560.00 thousand (+5.15%).
- TRVI quarterly EBITDA is now -161.05% below its all-time high of -$3.95 million, reached on March 31, 2018.
Performance
TRVI quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$47.23M+$560.00K(+1.17%)Summary
- As of today (July 1, 2025), TRVI TTM EBITDA is -$47.23 million, with the most recent change of +$560.00 thousand (+1.17%) on March 31, 2025.
- Over the past year, TRVI TTM EBITDA has dropped by -$13.93 million (-41.84%).
- TRVI TTM EBITDA is now -1095.42% below its all-time high of -$3.95 million, reached on March 31, 2018.
Performance
TRVI TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TRVI EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -67.2% | +5.2% | -41.8% |
| 3 y3 years | -46.1% | -46.9% | -49.2% |
| 5 y5 years | -83.6% | -21.7% | -58.8% |
TRVI EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -70.8% | at low | -97.0% | +22.1% | -81.3% | +1.2% |
| 5 y | 5-year | -83.6% | at low | -97.0% | +22.1% | -81.3% | +1.2% |
| alltime | all time | -400.9% | at low | -161.1% | +22.1% | -1095.4% | +1.2% |
TRVI EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$10.31M(-9.2%) | -$47.23M(-1.2%) |
| Dec 2024 | -$47.79M(+67.2%) | -$11.36M(-14.2%) | -$47.79M(+8.1%) |
| Sep 2024 | - | -$13.24M(+7.4%) | -$44.20M(+14.4%) |
| Jun 2024 | - | -$12.32M(+13.3%) | -$38.63M(+16.0%) |
| Mar 2024 | - | -$10.87M(+40.1%) | -$33.30M(+16.5%) |
| Dec 2023 | -$28.58M(+2.1%) | -$7.76M(+1.2%) | -$28.58M(+9.7%) |
| Sep 2023 | - | -$7.67M(+9.8%) | -$26.05M(-1.1%) |
| Jun 2023 | - | -$6.99M(+13.5%) | -$26.35M(-2.8%) |
| Mar 2023 | - | -$6.16M(+17.6%) | -$27.12M(-3.1%) |
| Dec 2022 | -$27.98M(-14.5%) | -$5.24M(-34.3%) | -$27.98M(-9.6%) |
| Sep 2022 | - | -$7.97M(+2.8%) | -$30.95M(+3.5%) |
| Jun 2022 | - | -$7.75M(+10.4%) | -$29.92M(-5.5%) |
| Mar 2022 | - | -$7.02M(-14.4%) | -$31.65M(-3.2%) |
| Dec 2021 | -$32.71M | -$8.21M(+18.3%) | -$32.71M(-2.9%) |
| Sep 2021 | - | -$6.94M(-26.9%) | -$33.69M(-0.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$9.49M(+17.4%) | -$33.98M(+6.6%) |
| Mar 2021 | - | -$8.08M(-12.0%) | -$31.88M(-1.2%) |
| Dec 2020 | -$32.27M(+24.0%) | -$9.19M(+27.1%) | -$32.27M(+9.0%) |
| Sep 2020 | - | -$7.23M(-2.2%) | -$29.62M(-0.4%) |
| Jun 2020 | - | -$7.39M(-12.8%) | -$29.75M(-0.1%) |
| Mar 2020 | - | -$8.47M(+29.7%) | -$29.77M(+14.1%) |
| Dec 2019 | -$26.03M(+27.1%) | -$6.53M(-11.2%) | -$26.10M(+2.0%) |
| Sep 2019 | - | -$7.36M(-0.6%) | -$25.59M(+7.0%) |
| Jun 2019 | - | -$7.41M(+54.2%) | -$23.90M(+12.1%) |
| Mar 2019 | - | -$4.80M(-20.2%) | -$21.32M(+4.2%) |
| Dec 2018 | -$20.47M(+114.6%) | -$6.02M(+6.0%) | -$20.47M(+41.6%) |
| Sep 2018 | - | -$5.67M(+17.5%) | -$14.45M(+64.6%) |
| Jun 2018 | - | -$4.83M(+22.2%) | -$8.78M(+122.2%) |
| Mar 2018 | - | -$3.95M | -$3.95M |
| Dec 2017 | -$9.54M | - | - |
FAQ
- What is Trevi Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Trevi Therapeutics?
- What is Trevi Therapeutics annual EBITDA year-on-year change?
- What is Trevi Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Trevi Therapeutics?
- What is Trevi Therapeutics quarterly EBITDA year-on-year change?
- What is Trevi Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Trevi Therapeutics?
- What is Trevi Therapeutics TTM EBITDA year-on-year change?
What is Trevi Therapeutics annual EBITDA?
The current annual EBITDA of TRVI is -$47.79M
What is the all time high annual EBITDA for Trevi Therapeutics?
Trevi Therapeutics all-time high annual EBITDA is -$9.54M
What is Trevi Therapeutics annual EBITDA year-on-year change?
Over the past year, TRVI annual EBITDA has changed by -$19.21M (-67.20%)
What is Trevi Therapeutics quarterly EBITDA?
The current quarterly EBITDA of TRVI is -$10.31M
What is the all time high quarterly EBITDA for Trevi Therapeutics?
Trevi Therapeutics all-time high quarterly EBITDA is -$3.95M
What is Trevi Therapeutics quarterly EBITDA year-on-year change?
Over the past year, TRVI quarterly EBITDA has changed by +$560.00K (+5.15%)
What is Trevi Therapeutics TTM EBITDA?
The current TTM EBITDA of TRVI is -$47.23M
What is the all time high TTM EBITDA for Trevi Therapeutics?
Trevi Therapeutics all-time high TTM EBITDA is -$3.95M
What is Trevi Therapeutics TTM EBITDA year-on-year change?
Over the past year, TRVI TTM EBITDA has changed by -$13.93M (-41.84%)